Abstract: Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide and pharmaceutically acceptable additives including at least one surfactant are made.

Abstract: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.

Abstract: Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

Abstract: The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.

Abstract: The present invention provides solid dosage formulations of benzoxazole-containing ER?-selective ligands, and processes for their manufacture, more particularly to novel formulations, and processes for their manufacture, that contain the ER?-selective ligand, ERB-041.

Abstract: The present invention relates to solid dosage formulations that include ER?-selective ligands that contain benzoxazole, and processes for manufacture of said formulations, more particularly to novel formulations and processes for manufacture of formulations containing the ER?-selective ligand, ERB-041.

Abstract: The present invention provides solid dosage formulations of benzoxazole-containing ER?-selective ligands, and processes for their manufacture.

Abstract: The present invention provides solid dosage formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives and processes for their manufacture. In some particular embodiments, the present invention provides novel formulations of the antipsychotic and antiobesity agent (9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c][1,4]diazepino[6,7,1-ij]quinoline hydrochloride (Compound A.HCl).